Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine

Xie,Xia; Tang,Bo; Zhou,Jianyun; Gao,Qing; Zhang,Pengbing

doi:10.3892/or.2013.2520

Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine

Authors:
- Xia Xie
- Bo Tang
- Jianyun Zhou
- Qing Gao
- Pengbing Zhang
View Affiliations

Affiliations: Department of Gastroenterology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, P.R. China, Department of Gastroenterology, First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: June 5, 2013 https://doi.org/10.3892/or.2013.2520
Pages: 773-782

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The phosphatidylinositol 3‑kinase (PI3K)/Akt signaling pathway plays a crucial role in tumorigenesis and tumor progression by promoting cell proliferation and inhibiting apoptosis, a process closely associated with multidrug resistance (MDR) of tumors. LY294002 is a commonly used pharmacological inhibitor that acts at the ATP‑binding site of the PI3K enzyme, selectively inhibiting the PI3K/Akt pathway. In the present study, we evaluated the effect of LY294002 on the chemosensitivity of gastric cancer cells to vincristine (VCR) in vitro and in vivo and investigated the possible underlying cellular mechanisms. The effect of LY294002 on cell viability, apoptosis induction and inhibition of tumor growth was analyzed using MTT and TUNEL assay in in vitro and in vivo models of gastric cancer. Intracellular accumulation of VCR was determined by high performance liquid chromatography. The activity of the PI3K/Akt pathway was evaluated by western blot analysis. Furthermore, reverse transcription PCR and immunohistochemistry were performed to determine the mRNA and protein expression levels of MDR1/ P-glycoprotein (P‑gp) and apoptosis‑related factors. We found that gastric cancer cells treated with LY294002 showed a significant inhibition of PI3K/Akt activity. The PI3K inhibitor LY294002 combined with VCR worked synergistically to promote growth inhibition, induce apoptosis and increase the intracellular drug accumulation in gastric cancer cell lines. Similarly, LY294002 could cooperate with VCR to reduce tumor growth in a gastric cancer model in vivo. Finally, LY294002 was able to decrease the expression of MDR1/P‑gp, Bcl‑2 and XIAP, and upregulate expression of Bax and caspase‑3, thereby enhancing chemosensitivity to VCR by inhibiting a drug pump and inducing apoptosis. These results suggested that the PI3K/Akt inhibitor LY294002 can enhance chemosensitivity of human gastric cancer to VCR. This preclinical evaluation of a rational combination of LY294002 and VCR may provide a new strategy to resolve the MDR of gastric cancer.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Plummer M, Franceschi S and Muñoz N: Epidemiology of gastric cancer. IARC Sci Publ. 157:311–326. 2004.
3	Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F and Van Cutsem E: Gastric cancer. Crit Rev Oncol Hematol. 71:127–164. 2009. View Article : Google Scholar
4	Ozeben T: Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 580:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
5	Gillet JP and Gottesman MM: Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 596:47–76. 2010. View Article : Google Scholar : PubMed/NCBI
6	Gillet JP, Efferth T and Remacle J: Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta. 1775:237–262. 2007.PubMed/NCBI
7	Callaghan R, Crowley E, Potter S and Kerr ID: P-glycoprotein: so many ways to turn it on. J Clin Pharmacol. 48:365–378. 2008. View Article : Google Scholar : PubMed/NCBI
8	Martin LP, Hamilton TC and Schilder RJ: Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
9	Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M and Wick W: Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 14:2900–2908. 2008. View Article : Google Scholar : PubMed/NCBI
10	Rodriguez-Nieto S and Zhivotovsky B: Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment. Curr Pharm Des. 12:4411–4425. 2006. View Article : Google Scholar : PubMed/NCBI
11	Viktorsson K, Lewensohn R and Zhivotovsky B: Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res. 94:143–196. 2005. View Article : Google Scholar : PubMed/NCBI
12	Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, Nicosia SV and Cheng JQ: AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci. 10:975–987. 2005. View Article : Google Scholar : PubMed/NCBI
13	Liu P, ChenG H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 8:627–644. 2009. View Article : Google Scholar : PubMed/NCBI
14	Courtney KD, Corcoran RB and Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol. 28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
15	Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30:193–204. 2004.PubMed/NCBI
16	Kunnimalaiyaan M, Ndiaye M and Chen H: Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery. 140:1009–1014. 2006. View Article : Google Scholar : PubMed/NCBI
17	Liu P, Xu B, Li J and Lu H: LY294002 inhibits leukemia cell invasion and migration through early growth response gene 1 induction independent of phosphatidylinositol 3-kinase-Akt pathway. Biochem Biophys Res Commun. 377:187–190. 2008. View Article : Google Scholar : PubMed/NCBI
18	Imai Y, Yoshimori M, Fukuda K, Yamagishi H and Ueda Y: The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. Oncol Rep. 27:1703–1709. 2012.PubMed/NCBI
19	Wu D, Tao J, Xu B, Qing W, Li P, Lu Q and Zhang W: Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells. Urol Int. 87:105–113. 2011. View Article : Google Scholar
20	Gelman AE, LaRosa DF, Zhang J, Walsh PT, Choi Y, Sunyer JO and Turka LA: The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4⁺ T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity. 25:783–793. 2006. View Article : Google Scholar : PubMed/NCBI
21	Crowell JA, Steele VE and Fay JR: Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther. 6:2139–2148. 2007. View Article : Google Scholar : PubMed/NCBI
22	Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
23	Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin EF III and Liotta LA: Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 20:1981–1989. 2001. View Article : Google Scholar : PubMed/NCBI
24	García MG, Alaniz LD, Cordo Russo RI, Alvarez E and Hajos SE: PI3K/Akt inhibition modulates multidrug resistance and activates NF-κB in murine lymphoma cell lines. Leuk Res. 33:288–296. 2009.PubMed/NCBI
25	Filipits M: Mechanisms of cancer: multidrug resistance. Drug Discov Today Dis Mech. 1:229–234. 2004. View Article : Google Scholar
26	Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe S, Mills GB and Unate H: Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-κB signaling. Oncogene. 21:1945–1954. 2002.PubMed/NCBI
27	Barancík M, Bohácová V, Sedlák J, Sulová Z and Breier A: LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci. 29:426–434. 2006.PubMed/NCBI
28	Gill PK, Gescher A and Gant TW: Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes α and θ. Eur J Biochem. 268:4151–4157. 2001.PubMed/NCBI
29	Vertegaal AC, Kuiperij HB, Yamaoka S, Courtois G, van der Eb AJ and Zantema A: Protein kinase C-α is an upstream activator of the IκB kinase complex in the TPA signal transduction pathway to NF-κB in U2OS cells. Cell Signal. 12:759–768. 2000.
30	Chao X, Zao J, Xiao-Yi G, Li-Jun M and Tao S: Blocking of PI3K/AKT induces apoptosis by its effect on NF-κB activity in gastric carcinoma cell line SGC7901. Biomed Pharmacother. 64:600–604. 2010.
31	Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
32	Nuutinen U, Postila V, Mättö M, Eeva J, Ropponen A, Eray M, Riikonen P and Pelkonen J: Inhibition of PI3-kinase-Akt pathway enhances dexamethasone-induced apoptosis in a human follicular lymphoma cell line. Exp Cell Res. 312:322–330. 2006.PubMed/NCBI
33	Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 55:178–194. 2005. View Article : Google Scholar : PubMed/NCBI
34	Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
35	Riedl SJ and Salvesen GS: The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol. 8:405–413. 2007. View Article : Google Scholar : PubMed/NCBI
36	Elumalai P, Gunadharini DN, Senthilkumar K, Banudevi S, Arunkumar R, Benson CS, Sharmila G and Arunakaran J: Induction of apoptosis in human breast cancer cells by nimbolide through extrinsic and intrinsic pathway. Toxicol Lett. 215:131–142. 2012. View Article : Google Scholar : PubMed/NCBI
37	Gillings AS, Balmanno K, Wiggins CM, Johnson M and Cook SJ: Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. FEBS J. 276:6050–6062. 2009. View Article : Google Scholar : PubMed/NCBI
38	Tait SW and Green DR: Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 11:621–632. 2010. View Article : Google Scholar : PubMed/NCBI
39	Kaufmann T, Strasser A and Jost PJ: Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ. 19:42–50. 2012. View Article : Google Scholar : PubMed/NCBI
40	Hussain AR, Ahmed SO, Ahmed M, Khan OS, Al Abdulmohsen S, Platanias LC, Al-Kuraya KS and Uddin S: Cross-talk between NFκB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One. 7:e399452012.
41	Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 441:424–430. 2006. View Article : Google Scholar : PubMed/NCBI
42	Nicholson KM and Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
43	Shant J, Cheng K, Marasa BS, Wang JY and Raufman JP: Akt-dependent NF-κB activation is required for bile acids to rescue colon cancer cells from stress-induced apoptosis. Exp Cell Res. 315:432–450. 2009.
44	Uchida M, Iwase M, Takaoka S, Yoshiba S, Kondo G, Watanabe H, Ohashi M, Nagumo M and Shintani S: Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors. Int J Oncol. 30:1163–1171. 2007.
45	Mantovani I, Cappellini A, Tazzari PL, Papa V, Cocco L and Martelli AM: Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells. J Cell Physiol. 207:836–844. 2006. View Article : Google Scholar : PubMed/NCBI
46	McDonald GT, Sullivan R, Paré GC and Graham CH: Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression. Exp Cell Res. 316:3197–3206. 2010. View Article : Google Scholar : PubMed/NCBI
47	Shingu T, Yamada K, Hara N, Moritake K, Osago H, Terashima M, Uemura T, Yamasaki T and Tsuchiya M: Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor. J Neurosurg. 98:154–161. 2003. View Article : Google Scholar : PubMed/NCBI